Combination platinum-based chemotherapy is the standard first-line treatment for advanced urothelial carcinoma, but most patients have disease progression within 9 months; the median overall survival is 14 to 15 months with cisplatin-based regimens and 9 to 10 months with carboplatin-based regimens. New research findings are summarized in a short video. https://nej.md/35OBRpy | The New England Journal of Medicine